Vicore Pharma´s board member Göran Arvidson has passed away
Vicore Pharma Holding (publ) (ticker:VICO). It is with great regret we today inform of board member Göran Arvidson sudden and unexpected death.
"We are deeply saddened by the sudden death of Göran Arvidson, who was the most recent addition to Vicore Pharma's Board of Directors. His business expertise and insights will be greatly missed. Our thoughts go out to his family, friends and colleagues." says Leif Darner, chairman of the board.
For further information, please contact:
Leif Darner, Chairman of the board
Tel: +46 705 79 04 62
This information is information that Vicore Pharma Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, at 14.30 CET on November 8, 2017
About Vicore Pharma Holding
Vicore Pharma develops drugs that act through the AT2 receptor. The company’s drug candidate C21 aims to improve the treatment of idiopathic pulmonary fibrosis, a rare disease for which C21 has been granted orphan drug designation both in the EU and the US. In addition, C21 is explored pre-clinically in a number of rare diseases where the AT2 receptor plays an important role. Vicore Pharma is based in Astra Zeneca's Bioventurehub in Mölndal. The company's share (VICO) is listed for trading on Nasdaq First North in Stockholm with Erik Penser Bank as Certified Adviser. For more information, see www.vicorepharma.com